Evidence map›Paper›PMID 37120096›Full record

ArticleNeurobiology of disease2023

FMRP phosphorylation and interactions with Cdh1 regulate association with dendritic RNA granules and MEF2-triggered synapse elimination.

Julia R Wilkerson, Marius F Ifrim, Arielle N Valdez-Sinon, Patricia Hahn, Jacob E Bowles, Gemma Molinaro, Aleksandra Janusz-Kaminska, Gary J Bassell, Kimberly M Huber

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Julia R WilkersonDepartment of Neuroscience, O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Marius F IfrimDepartment of Cell and Developmental Biology, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA; Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Arielle N Valdez-SinonDepartment of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Patricia HahnDepartment of Neuroscience, O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Jacob E BowlesDepartment of Neuroscience, O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Gemma MolinaroDepartment of Neuroscience, O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Aleksandra Janusz-KaminskaDepartment of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Gary J BassellDepartment of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: gbassel@emory.edu.
Kimberly M HuberDepartment of Neuroscience, O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA. Electronic address: Kimberly.Huber@UTSouthwestern.edu.
Emory University · USThe University of Texas Southwestern Medical Center · USSouthwestern Medical Center

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Translational medicine and mechanistic studies of brain neurophysiology in Fragile X SyndromeU54HD104461 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI HUBER, KIMBERLY M. · 2020 to 2024
$8.1M
Medical Scientist Training ProgramT32GM142617 · NIGMS · EMORY UNIVERSITY · PI Jason Yustein · 2022 to 2026
$7.0M
Study of Fragile X Mental Retardation Protein in Synaptic Function and PlasticityR01HD052731 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI GIBSON, JAY ROBERT, HUBER, KIMBERLY M. · 2008 to 2022
$6.0M
FMRP Mechanism and FunctionR01MH109026 · NIMH · EMORY UNIVERSITY · PI BASSELL, GARY J · 2016 to 2020
$2.0M
NICHD NIH HHS R01 HD052731NICHD NIH HHS U54 HD104461NIGMS NIH HHS T32 GM142617NIMH NIH HHS R01 MH109026
6 · The paper itself

Abstract

Fragile X Messenger Ribonucleoprotein (FMRP) is necessary for experience-dependent, developmental synapse elimination and the loss of this process may underlie the excess dendritic spines and hyperconnectivity of cortical neurons in Fragile X Syndrome, a common inherited form of intellectual disability and autism. Little is known of the signaling pathways that regulate synapse elimination and if or how FMRP is regulated during this process. We have characterized a model of synapse elimination in CA1 neurons of organotypic hippocampal slice cultures that is induced by expression of the active transcription factor Myocyte Enhancer Factor 2 (MEF2) and relies on postsynaptic FMRP. MEF2-induced synapse elimination is deficient in Fmr1 KO CA1 neurons, and is rescued by acute (24 h), postsynaptic and cell autonomous reexpression of FMRP in CA1 neurons. FMRP is an RNA binding protein that suppresses mRNA translation. Derepression is induced by posttranslational mechanisms downstream of metabotropic glutamate receptor signaling. Dephosphorylation of FMRP at S499 triggers ubiquitination and degradation of FMRP which then relieves translation suppression and promotes synthesis of proteins encoded by target mRNAs. Whether this mechanism functions in synapse elimination is not known. Here we demonstrate that phosphorylation and dephosphorylation of FMRP at S499 are both necessary for synapse elimination as well as interaction of FMRP with its E3 ligase for FMRP, APC/Cdh1. Using a bimolecular ubiquitin-mediated fluorescence complementation (UbFC) assay, we demonstrate that MEF2 promotes ubiquitination of FMRP in CA1 neurons that relies on activity and interaction with APC/Cdh1. Our results suggest a model where MEF2 regulates posttranslational modifications of FMRP via APC/Cdh1 to regulate translation of proteins necessary for synapse elimination.

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeAnimalsMEF2 Transcription FactorsMiceMice, KnockoutPhosphorylationRibonucleoproteinsSynapsesFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1MEF2 Transcription Factorsmessenger ribonucleoproteinRibonucleoproteinsCdh1FMRPHippocampal CA1MEF2Synapse elimination

Identifiers

PMID37120096
PMCPMC10370323
OpenAlexW4367299818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.